Dermatology

Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

The oral Janus kinase 1 inhibitor abrocitinib produced similar outcomes to dupilumab in a placebo-controlled comparison for atopic dermatitis.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.

An expert offers his perspective on the investigative SLP receptor modulator for atopic dermatitis.

A dermatologist discusses some of her most common cosmetic practices and techniques.

Valerie Callender, MD, gives an overview of her practice and discusses the challenges during the COVID-19 pandemic.

Valerie Callender, MD, draws on her experiences in clinical practice to discuss cosmetic dermatology care practices and the challenges of this past year.

The study underscores the importance of interpreting patient-reported disease severity scores in the context of mental health factors.

Treatment showed a similar effect on patients with and without baseline asthma.

According to a systematic review and meta-analysis of 8776 unique patients, 52.69% achieved repigmentation of >90%.

Two studies demonstrated that the IL-17A and IL-17F inhibitor can lead to superior levels of skin of clearance in adult patients compared with ustekinumab or placebo. .